Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Recruiting

Phase 1

Phase 2

AZD9574Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Sponsor:

AstraZeneca

Code:

NCT05417594

Conditions

Advanced Solid Malignancies

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AZD9574

Temozolomide (TMZ)

[11C]AZ1419 3391

Datopotamab Deruxtecan (Dato-DXd)

Trastuzumab Deruxtecan (T-DXd)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-29. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-05-28.